2016 American Transplant Congress
Black Ethnicity as a Risk Factor for Poor Kidney Allograft Outcomes Post-Transplantation.
Introduction: Registry studies, largely from the United States, have consistently demonstrated inferior outcomes for black patients undergoing renal transplant. A recent Canadian publication has challenged…2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…2016 American Transplant Congress
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.
While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…2016 American Transplant Congress
Hepatitis E Virus (HEV) Infection Among Kidney Transplant Patients in a Northeast US Center.
Aim. To determine the prevalence of HEV infection in kidney candidates and assess chronic HEV infection among transplant recipients. Methods. We recruited 244 kidney transplant…2016 American Transplant Congress
An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.
Aims: To prospectively investigate the efficacy and safety of procedural HBV vaccination in patients transplanted for HBV related liver diseases for prevention of hepatitis B…2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…2016 American Transplant Congress
Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.
Background:DAA-treatment of hepatitis C virus (HCV) re-infections in orthotopic liver transplant (OLT) recipients has been demonstrated to be safe and effective in controlled studies, but…2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
American Transplant Congress abstracts